This article was originally published in The Gray Sheet
Executive SummaryBeginning in 2012, hospitals could get an increased or decreased Medicare payment depending on how well they perform on certain standard quality measures in the treatment of heart attack, heart failure, pneumonia and surgical care, under draft legislation being circulated by the Senate Finance Committee. Chairman Max Baucus, D-Mont., and ranking member Chuck Grassley, R-Iowa, released their value-based purchasing "discussion draft" Nov. 19 and are asking for public comments on the language by Dec. 15. The legislation is intended to build on the 2003-mandated Medicare policy to adjust hospital payments based simply on whether a facility simply reports certain quality measure outcomes
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.